NI
DGX icon

Nuance Investments’s Quest Diagnostics DGX Stock Holding History

Nuance Investments’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.81M Sell
24,540
-31,016
-56% -$6.03M 0.67% 27
2025
Q4 		$9.64M Buy
55,556
+25,349
+84% +$4.62M 1.06% 24
2025
Q3 		$5.76M Buy
+30,207
New +$5.36M 0.59% 34
2024
Q2 		– Sell
-681,636
Closed -$90.7M – 53
2024
Q1 		$90.7M Buy
681,636
+79,152
+13% +$10.3M 2.38% 14
2023
Q4 		$83.1M Buy
+602,484
New +$79.2M 1.9% 19

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Nuance Investments's DGX Position: Q1 2026 in Review

Nuance Investments reduced its Quest Diagnostics (DGX) stake by 56% in Q1 2026, selling an estimated $6.03M and leaving 24,540 shares worth $4.81M. The position accounts for 0.67% of the portfolio, ranked #27.

Nuance Investments first reported a position in DGX in Q4 2023 and has held it in 5 quarters since. The position peaked at $90.7M in Q1 2024. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Nuance Investments held 24,540 shares of Quest Diagnostics worth $4.81M as of Q1 2026.
  • Nuance Investments sold 31,016 Quest Diagnostics shares in Q1 2026, an estimated $6.03M.
  • Quest Diagnostics made up 0.67% of Nuance Investments's portfolio in Q1 2026, its #27 holding.
  • Nuance Investments first reported a position in Quest Diagnostics in Q4 2023 and has held it in 5 quarters since.
  • Nuance Investments's Quest Diagnostics position peaked at $90.7M in Q1 2024.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Nuance Investments's 13F filing for Q1 2026, filed 8 May 2026.